Logo image of XOMA

XOMA ROYALTY CORPORATION (XOMA) Stock Fundamental Analysis

USA - NASDAQ:XOMA - US98419J2069 - Common Stock

36.68 USD
+0.97 (+2.72%)
Last: 9/26/2025, 8:00:02 PM
38.5 USD
+1.82 (+4.96%)
Pre-Market: 9/29/2025, 8:00:06 AM
Fundamental Rating

4

XOMA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 536 industry peers in the Biotechnology industry. XOMA has a medium profitability rating, but doesn't score so well on its financial health evaluation. XOMA has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

XOMA had negative earnings in the past year.
In the past year XOMA has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: XOMA reported negative net income in multiple years.
In multiple years XOMA reported negative operating cash flow during the last 5 years.
XOMA Yearly Net Income VS EBIT VS OCF VS FCFXOMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

XOMA has a Return On Assets of -7.93%. This is amongst the best in the industry. XOMA outperforms 84.89% of its industry peers.
Looking at the Return On Equity, with a value of -19.17%, XOMA belongs to the top of the industry, outperforming 85.07% of the companies in the same industry.
XOMA has a better Return On Invested Capital (3.73%) than 91.60% of its industry peers.
Industry RankSector Rank
ROA -7.93%
ROE -19.17%
ROIC 3.73%
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
XOMA Yearly ROA, ROE, ROICXOMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

XOMA has a Operating Margin of 21.23%. This is amongst the best in the industry. XOMA outperforms 94.78% of its industry peers.
XOMA does not have Profit Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM 21.23%
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XOMA Yearly Profit, Operating, Gross MarginsXOMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

3

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so XOMA is destroying value.
XOMA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, XOMA has more shares outstanding
XOMA has a worse debt/assets ratio than last year.
XOMA Yearly Shares OutstandingXOMA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
XOMA Yearly Total Debt VS Total AssetsXOMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -4.87, we must say that XOMA is in the distress zone and has some risk of bankruptcy.
XOMA has a Altman-Z score of -4.87. This is comparable to the rest of the industry: XOMA outperforms 40.30% of its industry peers.
XOMA has a Debt/Equity ratio of 1.11. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.11, XOMA is doing worse than 77.43% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF N/A
Altman-Z -4.87
ROIC/WACC0.36
WACC10.29%
XOMA Yearly LT Debt VS Equity VS FCFXOMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

XOMA has a Current Ratio of 4.88. This indicates that XOMA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.88, XOMA is in line with its industry, outperforming 52.80% of the companies in the same industry.
A Quick Ratio of 4.88 indicates that XOMA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.88, XOMA is in line with its industry, outperforming 54.66% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.88
Quick Ratio 4.88
XOMA Yearly Current Assets VS Current LiabilitesXOMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

XOMA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -38.74%.
Looking at the last year, XOMA shows a very strong growth in Revenue. The Revenue has grown by 168.71%.
XOMA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.17% yearly.
EPS 1Y (TTM)-38.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.62%
Revenue 1Y (TTM)168.71%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%18.39%

3.2 Future

Based on estimates for the next years, XOMA will show a very strong growth in Earnings Per Share. The EPS will grow by 37.32% on average per year.
XOMA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 35.53% yearly.
EPS Next Y126.86%
EPS Next 2Y49.97%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue Next Year85%
Revenue Next 2Y45.1%
Revenue Next 3Y35.53%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
XOMA Yearly Revenue VS EstimatesXOMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M
XOMA Yearly EPS VS EstimatesXOMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -2 -4 -6 -8 -10

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

XOMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
XOMA is valuated quite expensively with a Price/Forward Earnings ratio of 71.46.
Based on the Price/Forward Earnings ratio, XOMA is valued cheaper than 87.87% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.05. XOMA is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 71.46
XOMA Price Earnings VS Forward Price EarningsXOMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

90.86% of the companies in the same industry are more expensive than XOMA, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 42.4
XOMA Per share dataXOMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

XOMA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as XOMA's earnings are expected to grow with 37.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y49.97%
EPS Next 3Y37.32%

More info and screens

0

5. Dividend

5.1 Amount

XOMA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XOMA ROYALTY CORPORATION

NASDAQ:XOMA (9/26/2025, 8:00:02 PM)

Premarket: 38.5 +1.82 (+4.96%)

36.68

+0.97 (+2.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-05 2025-11-05
Inst Owners68.05%
Inst Owner Change4.12%
Ins Owners1.4%
Ins Owner Change-10.05%
Market Cap443.46M
Analysts82
Price Target71.06 (93.73%)
Short Float %2.22%
Short Ratio5.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.47
Dividend Growth(5Y)N/A
DP-30.88%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)207.59%
Min EPS beat(2)119.7%
Max EPS beat(2)295.48%
EPS beat(4)2
Avg EPS beat(4)28.19%
Min EPS beat(4)-256.98%
Max EPS beat(4)295.48%
EPS beat(8)3
Avg EPS beat(8)57.63%
EPS beat(12)4
Avg EPS beat(12)26.41%
EPS beat(16)5
Avg EPS beat(16)-3.83%
Revenue beat(2)2
Avg Revenue beat(2)76.76%
Min Revenue beat(2)32.7%
Max Revenue beat(2)120.82%
Revenue beat(4)3
Avg Revenue beat(4)39.95%
Min Revenue beat(4)-2.38%
Max Revenue beat(4)120.82%
Revenue beat(8)5
Avg Revenue beat(8)13.46%
Revenue beat(12)7
Avg Revenue beat(12)9.54%
Revenue beat(16)8
Avg Revenue beat(16)-1.84%
PT rev (1m)7.73%
PT rev (3m)7.73%
EPS NQ rev (1m)0%
EPS NQ rev (3m)78.18%
EPS NY rev (1m)52.1%
EPS NY rev (3m)198.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)8.53%
Revenue NY rev (1m)3.63%
Revenue NY rev (3m)10.53%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 71.46
P/S 9.87
P/FCF N/A
P/OCF N/A
P/B 4.8
P/tB 9.43
EV/EBITDA 42.4
EPS(TTM)-1.54
EYN/A
EPS(NY)0.51
Fwd EY1.4%
FCF(TTM)-1.91
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS3.72
BVpS7.65
TBVpS3.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.93%
ROE -19.17%
ROCE 4.73%
ROIC 3.73%
ROICexc 6.38%
ROICexgc 10.37%
OM 21.23%
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 1.11
Debt/FCF N/A
Debt/EBITDA 9.33
Cap/Depr 1425.07%
Cap/Sales 44.89%
Interest Coverage 0.78
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.88
Quick Ratio 4.88
Altman-Z -4.87
F-Score5
WACC10.29%
ROIC/WACC0.36
Cap/Depr(3y)7738.51%
Cap/Depr(5y)4653.1%
Cap/Sales(3y)108.05%
Cap/Sales(5y)64.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.62%
EPS Next Y126.86%
EPS Next 2Y49.97%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue 1Y (TTM)168.71%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%18.39%
Revenue Next Year85%
Revenue Next 2Y45.1%
Revenue Next 3Y35.53%
Revenue Next 5YN/A
EBIT growth 1Y141.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year177.34%
EBIT Next 3Y51.87%
EBIT Next 5YN/A
FCF growth 1Y34.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y85.47%
OCF growth 3YN/A
OCF growth 5YN/A